Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + abiraterone neoadjuvant study in oligometastatic hormone-sensitive prostate cancer
ChiCTR2100050150Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and abiraterone in prostate cancer (PCa), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Pathological complete response rate and Pathologically significant response rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
fluzoparibabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2100050150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050150.